The present invention relates to novel compounds that are inhibitors of Rearranged during Transfection (RET) kinases, pharmaceutical compositions containing them, methods for their production, and gastrointestinal hypersensitivity, motility and / or secretion and / or abdomen. Normalization of disorder or disease, and / or RET dysfunction, but not limited to, diarrhea type, constipation type or alternating defecation pattern, functional bloating, functional constipation, functional diarrhea, Unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorder, functional gastroduodenal disorder, functional anorectal pain, irritable bowel syndrome (IBS) including inflammatory bowel disease； Small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, undifferentiated thyroid cancer, papillary thyroid cancer, brain tumor, abdominal cancer, solid tumor, other lung cancer, head and neck cancer, nerve , Neuroblastoma, von Hippel-Lindau syndrome and kidney tumor, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell carcinoma, prostate cancer, cancer of the esophagus and gastroesophageal junction, bile duct cancer, adenocarcinoma, and high RET kinase It relates to their use in monotherapy or combination therapy for the treatment of diseases where modulation of RET activity may have therapeutic benefit, including all classifications of proliferative diseases such as any malignant tumor with activity.本発明は、Rearranged during Transfection（ＲＥＴ）キナーゼの阻害剤である新規な化合物、それらを含有する医薬組成物、それらの製造方法、ならびに消化管過敏性、運動性および／または分泌性および／または腹部障害または疾患の正常化、および／またはＲＥＴ機能不全に関連するか、または限定されるものではないが、下痢型、便秘型または交互型排便パターン、機能性鼓脹、機能性便秘、機能性下痢、特定不能の機能性腸障害、機能性腹痛症候群、慢性特発性便秘、機能性食道障害、機能性胃十二指腸障害、機能性肛門直腸痛、炎症性腸疾患を含む過敏性腸症候群（ＩＢＳ）；非小細胞肺癌、肝細胞癌、結腸直腸癌、甲状腺髄様癌、濾胞性甲状腺癌、未分化甲状腺癌、甲状腺乳頭癌、脳腫瘍、腹腔癌、固形腫瘍、他の肺癌、頭頸部癌、神経膠腫、神経芽腫、フォンヒッペル－リンドウ症候群および腎臓腫瘍、乳癌、卵管癌、卵巣癌、移行上皮癌、前立腺癌、食道および胃食道接合部の癌、胆管癌、腺癌、および高いＲＥＴ
